Africa

9766

By D. Adam Togba | Contributor

Patients currently receiving care for Mpox at the Emergency Treatment Unit (ETU) of the Liberia Center for Infectious Diseases (LCID) at Star Base, Bong Mines Bridge, have raised serious concerns over the shortage of essential drugs at the facility calling on the Liberian government and its international partners to intervene immediately.

Several patients, including journalists and other professionals admitted at the center, told this reporter via mobile phone that nurses are urging them to purchase their own medicines because the facility has run out of key supplies.

“When we got here, we were surprised to be told to call our family members to bring medicines such as Acyclovir tablets and Vitamin C. Some of these medicines cost more than ten U.S. dollars, and not everyone can afford them,” a patient disclosed.

According to the patients, Acyclovir, an antiviral drug, is being recommended as the main treatment at the center. However, scientific evidence indicates that Acyclovir is not effective against Mpox. It is commonly used for infections caused by the herpes simplex virus and varicella-zoster virus—not the Orthopoxvirus responsible for Mpox.

Medical experts have confirmed that the approved antiviral drug for severe Mpox cases is Tecovirimat (TPOXX), while prevention depends on vaccination and reducing exposure through public awareness.

This revelation raises serious public health concerns, especially as patients many of whom are isolated and stigmatized depend entirely on the state for treatment and recovery.

“It is frustrating that the treatment center is asking us to buy drugs from outside. We are already sick and under pressure. The government and its partners need to step in now,” another patient pleaded.

Despite the medical supply gap, the patients commended the general condition of the facility, describing it as “standard and comfortable,” with reliable electricity, running water, decent bathrooms, air conditioning, and well-prepared meals served three times daily.

“The place is clean, and the environment is well managed. But what is the use if we have no proper medication?” one of the patients lamented.

Meanwhile, the number of new Mpox cases continues to rise daily. Patients say most people come to the center on their own not because of government awareness, but because of social stigma and rejection in their communities.

“People see the rashes on your skin and start avoiding you. That is why some of us came here. But in many communities, people are still infected and taking treatments for sexually transmitted infections because they don’t know what Mpox looks like,” a patient explained.

Health experts have repeatedly warned that limited public education on Mpox symptoms and prevention could worsen the spread of the disease. Many Liberians reportedly remain unaware that vaccines exist for high-risk groups in the country.

As the crisis deepens, patients and concerned citizens are appealing to the Ministry of Health, National Public Health Institute of Liberia (NPHIL), and international partners such as the World Bank, which is reportedly providing major support to the treatment center, to act urgently.

“We appreciate the World Bank’s support, but the government must ensure that the ETU has adequate drugs. There should also be a national awareness campaign to stop the spread,” said one patient on behalf of others.

The situation at the LCID ETU underscores an urgent need for stronger coordination among Liberia’s health authorities and partners to ensure that patients receive the right treatment—and that public communication keeps pace with the growing threat of Mpox in the country.

Back to top button